MK-3795

DRUG2 trials

Sponsors

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions

Clear Cell RCCClear Cell Renal Cell CarcinomaKidney CancerRCCRenal Cell CarcinomaVHLVHL Gene InactivationVHL Gene Mutation

Phase 1

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Active, not recruitingNCT02293980

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer +2

Start: 2014-11-25End: 2026-11-30Updated: 2024-06-17

Phase 2

MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)

CompletedNCT03108066

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)ccRCC, Clear Cell RCC, Clear Cell Renal Cell Carcinoma +8

Start: 2017-04-24End: 2023-09-27Updated: 2024-09-24

Related Papers

Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.

Journal of Clinical Oncology2019-03-0122 citations

A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.

Journal of Clinical Oncology2016-05-206 citations